banner image

Psychedelic-Assisted Therapy

“The real medicine is the therapeutic relationship and psychedelics beautifully amplify that.”
— Dr. Rosalind Watts —

By April 2024, I will be fully trained by the Integrative Psychiatry Institute (an affiliate of the Multidisciplinary Association for Psychedelic Studies) to provide psychedelic-assisted therapy using ketamine, MDMA and psilocybin.

Currently, ketamine is the only psychedelic that has been FDA-approved for therapeutic use in a clinical setting, though MDMA clinical trials are undergoing their final review, and psilocybin has progressed to a final round of clinical trials. It is expected that MDMA should be approved for therapeutic use by early 2024, and psilocybin will not be far behind.

Ketamine-assisted psychotherapy options are now available at Deeper Well Therapy, and MDMA-assisted options will hopefully also become available as soon as those are FDA-approved. I am partnering with Journey Clinical to provide medical evaluations, prescribing and supplies at the most accessible rates I’ve been able to find. My hope is that making this option available through my practice will make psychedelic therapy more accessible from the very beginning, and as long as I offer it.

I may re-establish my practice in a physical location in upstate New York (in the Catskills) by the end of 2024 where I would plan to make in-person ketamine therapy options available, and hopefully also MDMA as soon as it’s approved.

I am so excited to be able to offer these powerful modalities as ways to help people recover from trauma, depression and anxiety, and experience more joy, connectedness and fulfillment in their lives. Please contact me with any questions you may have about current and future psychedelic therapy options.

Values That Guide My Psychedelic Practice:

  • TRUST (. . . in the inner healing intelligence of each client and their process, primarily. But also in the therapy container itself, cultivated through adherence to the highest ethical standards)
  • ACCESSIBILITY (through a pay-it-forward sliding scale fee schedule)
  • DIVERSITY (by collaborating with BIPOC in ongoing training, professional collaborations and consultation, and eventually, by bringing BIPOC onto the team if I expand beyond a solo practice)
  • INCLUSION (by centering traditionally marginalized voices and continually acknowledging the origins of psychedelic medicine in indigenous cultures around the world, and the contributions of women in the psychedelic space)
  • RECIPROCITY (by making reparations to BIPOC communities from whose psychedelic medicine practices our current clinical models originate through ongoing acknowledgment, cultural humility, and increasing accessibility through a pay-it-forward fee model)